AbbVie Inc. (NYSE: ABBV) announced today that it has agreed to acquire ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company focused on developing antibody-drug conjugates (ADCs) for the treatment of cancer. The deal values ImmunoGen at $31.26 per share in cash, or about $10.1 billion in total. The acquisition will give AbbVie access to ImmunoGen’s flagship…
Tag: AbbVie Inc.
AbbVie Inc.
AbbVie Inc. is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. Traded as: NYSE: ABBV; S&P 100 component; S&P 500 component Industry: Biopharmaceutical Founded: 2013; 7 years ago Headquarters: Lake Bluff, Illinois, United States Products: Pharmaceutical drugs Website: www.abbvie.com